STOCK TITAN

Armata Pharmaceuticals, Inc. - ARMP STOCK NEWS

Welcome to our dedicated news page for Armata Pharmaceuticals (Ticker: ARMP), a resource for investors and traders seeking the latest updates and insights on Armata Pharmaceuticals .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Armata Pharmaceuticals 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Armata Pharmaceuticals 's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.57%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.36%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7%
Tags
none
Armata Pharmaceuticals, Inc.

NYSE:ARMP

ARMP Rankings

ARMP Stock Data

93.98M
10.72M
70.35%
3.59%
0.04%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
LOS ANGELES

About ARMP

c3 jian is a well-capitalized, private, los angeles based biotechnology company advancing novel compounds that target unmet medical/dental needs related primarily to oral healthcare. the company's lead compound is a unique peptide drug against dental caries (i.e. tooth decay). the company’s lead compound started fda-regulated phase ii human clinical trials in early 2014. c3 jian's platform technology has also yielded peptides that can affect calcification processes, including not only tooth sensitivity but possibly hair and nail growth as well. the company has recently moved its operations to a new facility in marina del rey. the company was founded based on technology created in the laboratory of dr. wenyuan shi, chair of the department of oral biology at the university of california, los angeles school of dentistry. for more information about the company and to explore career opportunities at c3 jian please visit our webpage at www.c3-jian.com